Abstract
Men in the San Francisco General Hospital (SFGH) public health system bear a substantially higher burden of high-risk disease than those in an academic or a community setting. Populations such as this would benefit most from targeted efforts for early detection and treatment to decrease prostate cancer morbidity and mortality.
Introduction
Since the introduction of the Prostate-Specific Antigen (PSA) test in the early 1990s, the landscape of prostate cancer diagnosis in the United States has shifted significantly toward earlier, lower-risk stages—a phenomenon known as "stage migration." However, much of the data supporting this trend originates from academic centers or private practices serving patients of higher socioeconomic status (SES). This study investigates whether this shift holds true for "safety net" hospitals like San Francisco General Hospital (SFGH), which primarily serve uninsured, Medicaid-dependent, and minority populations.
Methods
Researchers conducted a retrospective cohort study comparing three distinct patient populations in San Francisco:
- SFGH Cohort (Safety Net): 377 men (76% nonwhite, largely uninsured or on Medicaid).
- CaPSURE (Community Benchmark): A national longitudinal registry of over 13,000 men from 31 academic and community practices.
- UCSF Tumor Registry (Academic Benchmark): 6,504 patients treated at an urban academic center.
Risk was quantified using two validated tools: the D’Amico Classification and the Cancer of the Prostate Risk Assessment (CAPRA) score (0–10), which predicts disease recurrence and mortality based on clinical features.
Key Results
The study found significant quantitative disparities in cancer presentation (p < 0.001). Patients at SFGH presented with more aggressive disease across all metrics. Specifically, 67% of SFGH patients had intermediate or high-risk disease, compared to much lower proportions in the comparison groups. Furthermore, 12.4% of SFGH patients presented with clinically advanced or metastatic disease (cT3a or higher), nearly triple the rate observed in the community-based CaPSURE registry (4.3%).
The mean CAPRA score at SFGH was 4.05, notably higher than CaPSURE (3.15) and UCSF (2.74). Median PSA levels were also significantly higher in the safety-net cohort (10.2 ng/ml vs. ~6.8 ng/ml in other groups).
Discussion and Insights
The data reveals a "two-tiered" reality of the PSA era. While approximately 39% of patients in academic and community settings presented with low-risk disease, only 28% of safety-net patients did. This suggests that socioeconomic barriers—such as lack of private insurance—prevent underserved populations from benefiting from modern early-detection trends.
The authors suggest that this disparity may stem from delayed access to care or potentially different biological stressors. They introduce the concept of "allostatic load"—the physiological wear and tear from chronic poverty-related stress—as a potential factor making cancer more aggressive in these populations. Insurance status served as a strong proxy for risk, with lack of private insurance correlating with advanced stage at presentation.
Conclusion
The burden of high-risk prostate cancer is disproportionately concentrated in safety-net health systems. While the study's retrospective nature and geographic focus are limitations, the findings underscore the urgent need for targeted early-detection programs in disadvantaged communities. Future research should investigate unique biological determinants of aggressive cancer in these populations to help bridge the mortality gap.
Summary updated